What's New

Nippon Kayaku launches Portrazza Injection, a human anti EGFR Monoclonal Antibody


Tokyo, Japan, November 22th, 2019 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Atsuhiro Wakumoto; hereinafter referred to as “Nippon Kayaku”) today announced that it has launched the “Portrazza Injection (generic name:necitumumab)”.

“Portrazza Injection” is a human anti-EGFR monoclonal antibody that Eli Lilly and Company has been selling in Europe and the US since 2015 as a therapeutic agent (market name: PortrazzaTM) for advanced or metastatic squamous non-small cell lung cancer. Nippon Kayaku took over the marketing authorization holder from Eli Lilly Japan on August 1st 2019, and have been preparing for the launch.

Nippon Kayaku currently sells 33 types of anti-cancer drugs, and is building a business foundation focusing on oncology. With launch of this product, we expect to make a significant contribution to cancer patients, their families and medical professionals.

Product namePortrazza Injection
Generic nameNecitumumab
IndicationsIn combination with gemcitabine and cisplatin, Advanced or recurrent squamous non-small cell lung cancer, not amenable to curative resection.
Dosage and administrationRecommended dose of Portrzza Injection is 800 mg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle.

[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.